Posted by Michael Wonder on 02 Dec 2016
Amgen and Allergan submit biosimilar marketing authorisation application to EMA for ABP 215, a biosimilar candidate to bevacizumab
2 December 2016 - Supported by phase 3 study in patients with non-squamous non-small-cell lung cancer.
Amgen and Allergan today announced the submission of a marketing authorisation application to the EMA for ABP 215, a biosimilar candidate to Avastin (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA.
"The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Amgen is committed to delivering medicines to patients worldwide and ABP 215 has the potential to offer an additional high-quality therapeutic option for patients diagnosed with cancer."
